Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 + Durvalumab in Advanced NSCLC
NCT03419559Phase 2Withdrawn
- Sponsor
- Iovance Biotherapeutics
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of LN-145 in non-small cell lung cancer (NSCLC), sponsored by Iovance Biotherapeutics. Planned start Feb 2018; status: withdrawn.
02
Drugs
LN-145
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03419559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419559.